SMT201500316B - Derivati di benzotiazolo come agenti anticancro - Google Patents
Derivati di benzotiazolo come agenti anticancroInfo
- Publication number
- SMT201500316B SMT201500316B SM201500316T SM201500316T SMT201500316B SM T201500316 B SMT201500316 B SM T201500316B SM 201500316 T SM201500316 T SM 201500316T SM 201500316 T SM201500316 T SM 201500316T SM T201500316 B SMT201500316 B SM T201500316B
- Authority
- SM
- San Marino
- Prior art keywords
- benzotiazole
- derivatives
- anticancer agents
- anticancer
- agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008307581 | 2008-12-02 | ||
JP2009125256 | 2009-05-25 | ||
PCT/JP2009/070447 WO2010064722A1 (en) | 2008-12-02 | 2009-12-01 | Benzothiazole derivatives as anticancer agents |
Publications (1)
Publication Number | Publication Date |
---|---|
SMT201500316B true SMT201500316B (it) | 2016-01-08 |
Family
ID=42026212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SM201500316T SMT201500316B (it) | 2008-12-02 | 2015-12-15 | Derivati di benzotiazolo come agenti anticancro |
Country Status (41)
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2162445B1 (en) * | 2007-06-05 | 2013-11-27 | Takeda Pharmaceutical Company Limited | Heterobicyclic compounds as kinase inhibitors |
WO2009025358A1 (ja) * | 2007-08-23 | 2009-02-26 | Takeda Pharmaceutical Company Limited | 複素環化合物およびその用途 |
US8445509B2 (en) | 2008-05-08 | 2013-05-21 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivatives and use thereof |
JP5579619B2 (ja) | 2008-12-01 | 2014-08-27 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
US9725427B2 (en) | 2012-03-16 | 2017-08-08 | Biohaven Pharmaceutical Holding Company Limited | Prodrugs of riluzole and their method of use |
US20150126533A1 (en) * | 2012-03-30 | 2015-05-07 | Takeda Pharmaceutical Company Limited | Administration of a raf inhibitor and a mek inhibitor in the treatment of melanoma |
WO2014031732A2 (en) | 2012-08-22 | 2014-02-27 | Cornell University | Methods for inhibiting fascin |
BR112015032539B1 (pt) | 2013-06-28 | 2022-07-12 | Beigene, Ltd | Compostos ureia tricíclicos fundidos como inibidores de raf cinase e/ou dímero de raf cinase e composição farmacêutica compreendendo os referidos compostos |
EP3013797B1 (en) | 2013-06-28 | 2018-01-03 | BeiGene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
CN103435572B (zh) * | 2013-07-16 | 2015-02-04 | 浙江医药高等专科学校 | 噻唑并环己烷类化合物、其制备方法和抗肿瘤用途 |
CN103408541B (zh) * | 2013-07-16 | 2015-04-01 | 浙江医药高等专科学校 | 吲哚取代的噻唑并环己烷类化合物、及其抗肿瘤用途 |
CN103382190B (zh) * | 2013-07-16 | 2015-01-14 | 浙江医药高等专科学校 | 一类噻唑并环己烷类化合物、其制备方法和用途 |
CN103435573B (zh) * | 2013-07-16 | 2015-04-01 | 浙江医药高等专科学校 | 苄基取代的噻唑并环己烷类化合物、其制备方法和用途 |
WO2016008048A1 (en) | 2014-07-15 | 2016-01-21 | Ontario Institute For Cancer Research | Methods and devices for predicting anthracycline treatment efficacy |
EP3236966B1 (en) * | 2014-12-23 | 2020-08-12 | DOT Therapeutics-1, Inc. | Combination of raf inhibitors and taxanes |
WO2017066664A1 (en) * | 2015-10-16 | 2017-04-20 | Millennium Pharmaceuticals, Inc. | Combination therapy including a raf inhibitor for the treatment of colorectal cancer |
WO2017165491A1 (en) * | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer |
EP3433275A1 (en) | 2016-03-24 | 2019-01-30 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
TW201735949A (zh) | 2016-03-24 | 2017-10-16 | 千禧製藥公司 | 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法 |
CN109053630B (zh) * | 2018-08-22 | 2022-04-01 | 中国人民解放军第二军医大学 | 一种苯并噻唑类衍生物及其用途 |
WO2020097398A1 (en) * | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
WO2020232445A1 (en) * | 2019-05-16 | 2020-11-19 | The Regents Of The University Of California | Modulators of pyrimidine nucleotide biosynthetic pathways |
TW202204350A (zh) | 2020-05-06 | 2022-02-01 | 美商雅捷可斯治療公司 | 作為jak2抑制劑之6-雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
CN112094248B (zh) * | 2020-09-17 | 2023-05-12 | 中国人民解放军海军军医大学 | 一种取代苯并噻唑类化合物及其用途 |
WO2023086319A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2399026A (en) * | 1941-02-06 | 1946-04-23 | Chem Ind Basel | Amides of 2-aminoarylenethiazoles |
US4096264A (en) | 1975-12-09 | 1978-06-20 | Merck & Co., Inc. | Certain substituted imidazo [1,2-a] pyridines |
CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
JP2001517699A (ja) | 1997-09-26 | 2001-10-09 | アスタ メディカ アクチエンゲゼルシャフト | セリン/トレオニンプロテインキナーゼ作用の変性のためのアザベンズイミダゾールを基礎とする化合物 |
CA2359244C (en) | 1999-01-13 | 2013-10-08 | Bayer Corporation | .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
BRPI0007487B8 (pt) * | 1999-01-13 | 2021-05-25 | Bayer Healthcare Llc | difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase |
WO2000042012A1 (en) * | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
CN1183114C (zh) * | 1999-01-22 | 2005-01-05 | 麒麟麦酒株式会社 | 喹啉衍生物及喹唑啉衍生物 |
BR0012046A (pt) | 1999-07-01 | 2002-05-14 | Ajinomoto Kk | Composto heterocìclico, composição farmacêutica, inibidor de ativação de ap-1 ou um inibidor da ativação de nf-kappab, inibidor da produção de citocina inflamatória, e, inibidor da produção de metaloprotease de matriz ou inibidor da expressão do fator de adesão de célula inflamatória |
SK287401B6 (sk) | 1999-11-05 | 2010-09-07 | Astrazeneca Ab | Deriváty chinazolínu, spôsob ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie |
WO2001057008A1 (en) | 2000-02-07 | 2001-08-09 | Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft | 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
NZ520640A (en) | 2000-02-15 | 2005-04-29 | Upjohn Co | Pyrrole substituted 2-indolinone protein kinase inhibitors |
JP2003525936A (ja) | 2000-03-06 | 2003-09-02 | スミスクライン ビーチャム パブリック リミテッド カンパニー | Rafキナーゼ阻害物質としてのイミダゾール誘導体 |
GB0005357D0 (en) | 2000-03-06 | 2000-04-26 | Smithkline Beecham Plc | Compounds |
YU96502A (sh) | 2000-06-21 | 2006-01-16 | F. Hoffmann-La Roche Ag. | Derivati benzotiazola |
DK1318992T3 (da) | 2000-09-21 | 2005-11-21 | Smithkline Beecham Plc | Imidazolderivater som Raf-kinaseinhibitorer |
KR100589032B1 (ko) | 2000-10-20 | 2006-06-14 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
AU2002232439A1 (en) * | 2000-11-29 | 2002-06-11 | Glaxo Group Limited | Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors |
GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
EP1423383B1 (en) | 2001-09-05 | 2008-08-06 | Smithkline Beecham Plc | Pyridine substituted furan derivatives as raf kinase inhibitors |
US20040192689A1 (en) | 2001-09-05 | 2004-09-30 | Dean David Kenneth | Heterocycle-carboxamide derivatives as raf kinase inhibitors |
GB0121494D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
GB0121488D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
EP1487824B1 (en) | 2002-03-01 | 2007-06-20 | SmithKline Beecham Corporation | Diamino-pyrimidines and their use as angiogenesis inhibitors |
CA2480638C (en) | 2002-03-29 | 2013-02-12 | Chiron Corporation | Substituted benzazoles and use thereof as raf kinase inhibitors |
US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
ES2423800T3 (es) | 2003-03-28 | 2013-09-24 | Novartis Vaccines And Diagnostics, Inc. | Uso de compuestos orgánicos para la inmunopotenciación |
US7378233B2 (en) * | 2003-04-12 | 2008-05-27 | The Johns Hopkins University | BRAF mutation T1796A in thyroid cancers |
DE10334663A1 (de) * | 2003-07-30 | 2005-03-10 | Merck Patent Gmbh | Harnstoffderivate |
DE10337942A1 (de) * | 2003-08-18 | 2005-03-17 | Merck Patent Gmbh | Aminobenzimidazolderivate |
PT1682126E (pt) | 2003-10-16 | 2009-10-02 | Novartis Vaccines & Diagnostic | Benzazois substituídos e sua utilização como inibidores da quinase raf |
CA2565200C (en) | 2004-05-07 | 2013-12-24 | Exelixis, Inc. | Raf modulators and methods of use |
MX2007001155A (es) | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
KR20060079098A (ko) | 2004-12-31 | 2006-07-05 | 주식회사 엘지생명과학 | 신규한([1,3]티아졸로[5,4-b]피리딘-2-일)-2-카르복사마이드유도체 |
WO2006076376A1 (en) | 2005-01-11 | 2006-07-20 | Medicinova, Inc. | Topical treatment of solid tumors and ocular neovascularization |
JP2008528585A (ja) * | 2005-01-26 | 2008-07-31 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
RU2420525C2 (ru) | 2005-07-11 | 2011-06-10 | Мицубиси Танабе Фарма Корпорейшн | Производные оксимов и их получение |
TWI387592B (zh) | 2005-08-30 | 2013-03-01 | Novartis Ag | 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法 |
GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
WO2007058482A1 (en) | 2005-11-16 | 2007-05-24 | Lg Life Sciences, Ltd. | Novel inhibitors of protein kinase |
SI2010528T1 (en) | 2006-04-19 | 2018-02-28 | Novartis Ag | 6-O-substituted benzoxazole and benzothiazole compounds and procedures for inhibiting CSF-1R signaling |
EP2058309A4 (en) | 2006-08-04 | 2010-12-22 | Takeda Pharmaceutical | CONDENSED HETEROCYCLIC COMPOUND |
BRPI0714665A2 (pt) | 2006-08-04 | 2012-03-13 | Takeda Pharmaceutical Company Limited | Composto, pró-droga, agente farmacêutico, e, método para a profilaxia ou tratamento do câncer |
JP4328820B2 (ja) | 2007-01-10 | 2009-09-09 | 田辺三菱製薬株式会社 | 医薬組成物 |
WO2008084873A1 (ja) | 2007-01-10 | 2008-07-17 | Mitsubishi Tanabe Pharma Corporation | オキシム誘導体 |
CN101260106A (zh) * | 2007-03-06 | 2008-09-10 | 中国药科大学 | Raf激酶抑制剂及其制备方法和用途 |
WO2008125633A2 (en) | 2007-04-13 | 2008-10-23 | Rikshospitalet - Radiumhospitalet Hf | Egfr inhibitors for treatment and diagnosis of metastatic prostate cancer |
EP2162552A4 (en) | 2007-05-11 | 2010-06-30 | Univ Johns Hopkins | BIOMARKERS FOR MELANOMES |
WO2008147782A1 (en) | 2007-05-23 | 2008-12-04 | Novartis Ag | Raf inhibitors for the treatment of thyroid cancer |
EP2162445B1 (en) | 2007-06-05 | 2013-11-27 | Takeda Pharmaceutical Company Limited | Heterobicyclic compounds as kinase inhibitors |
JP2008307581A (ja) | 2007-06-15 | 2008-12-25 | Sanyo Special Steel Co Ltd | 管材の洗浄装置 |
WO2009025358A1 (ja) | 2007-08-23 | 2009-02-26 | Takeda Pharmaceutical Company Limited | 複素環化合物およびその用途 |
WO2009028629A1 (ja) | 2007-08-29 | 2009-03-05 | Takeda Pharmaceutical Company Limited | 複素環化合物およびその用途 |
WO2009028655A1 (ja) | 2007-08-30 | 2009-03-05 | Takeda Pharmaceutical Company Limited | 複素環化合物およびその用途 |
JP2009125256A (ja) | 2007-11-22 | 2009-06-11 | Kandado:Kk | 安眠枕 |
CN101220024A (zh) * | 2007-12-11 | 2008-07-16 | 杜晓敏 | 一组抑制激酶的抗癌化合物 |
WO2009099991A2 (en) | 2008-01-31 | 2009-08-13 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
US20090275546A1 (en) * | 2008-04-10 | 2009-11-05 | Istituto Superiore Di Sanita | Diagnostic tests and personalized treatment regimes for cancer stem cells |
US8445509B2 (en) | 2008-05-08 | 2013-05-21 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivatives and use thereof |
-
2009
- 2009-11-25 JO JOP/2009/0448A patent/JO3101B1/ar active
- 2009-12-01 ME MEP-2016-203A patent/ME02331B/me unknown
- 2009-12-01 EA EA201170735A patent/EA019447B1/ru not_active IP Right Cessation
- 2009-12-01 NZ NZ593759A patent/NZ593759A/en not_active IP Right Cessation
- 2009-12-01 GE GEAP200912278A patent/GEP20146003B/en unknown
- 2009-12-01 PL PL09775337T patent/PL2358689T3/pl unknown
- 2009-12-01 DK DK09775337.0T patent/DK2358689T5/en active
- 2009-12-01 MY MYPI20112494 patent/MY150989A/en unknown
- 2009-12-01 CN CN200980155786.1A patent/CN102300854B/zh not_active Expired - Fee Related
- 2009-12-01 EP EP09775337.0A patent/EP2358689B9/en active Active
- 2009-12-01 MX MX2011005836A patent/MX2011005836A/es active IP Right Grant
- 2009-12-01 WO PCT/JP2009/070447 patent/WO2010064722A1/en active Application Filing
- 2009-12-01 UY UY0001032281A patent/UY32281A/es not_active Application Discontinuation
- 2009-12-01 HU HUE09775337A patent/HUE026491T4/en unknown
- 2009-12-01 KR KR1020117015343A patent/KR101639092B1/ko active IP Right Grant
- 2009-12-01 PT PT97753370T patent/PT2358689E/pt unknown
- 2009-12-01 RS RS20150768A patent/RS54370B9/sr unknown
- 2009-12-01 TW TW098140940A patent/TWI436987B/zh not_active IP Right Cessation
- 2009-12-01 CA CA2745144A patent/CA2745144C/en active Active
- 2009-12-01 BR BRPI0922109-3A patent/BRPI0922109A2/pt not_active IP Right Cessation
- 2009-12-01 AR ARP090104620A patent/AR074435A1/es active IP Right Grant
- 2009-12-01 ES ES09775337.0T patent/ES2557304T3/es active Active
- 2009-12-01 AU AU2009323274A patent/AU2009323274B2/en not_active Ceased
- 2009-12-01 US US12/628,697 patent/US8143258B2/en not_active Expired - Fee Related
- 2009-12-01 PE PE2011001128A patent/PE20110588A1/es active IP Right Grant
- 2009-12-01 SG SG2011038247A patent/SG171426A1/en unknown
- 2009-12-01 SI SI200931334T patent/SI2358689T1/sl unknown
- 2009-12-01 JP JP2011538209A patent/JP5640014B2/ja not_active Expired - Fee Related
-
2011
- 2011-05-26 IL IL213184A patent/IL213184A0/en active IP Right Grant
- 2011-05-30 TN TN2011000280A patent/TN2011000280A1/fr unknown
- 2011-06-01 CL CL2011001299A patent/CL2011001299A1/es unknown
- 2011-06-01 DO DO2011000165A patent/DOP2011000165A/es unknown
- 2011-06-23 ZA ZA2011/04659A patent/ZA201104659B/en unknown
- 2011-06-24 CR CR20110366A patent/CR20110366A/es unknown
- 2011-06-29 EC EC2011011165A patent/ECSP11011165A/es unknown
- 2011-06-30 CO CO11082152A patent/CO6400140A2/es active IP Right Grant
- 2011-06-30 MA MA33985A patent/MA32911B1/fr unknown
-
2012
- 2012-01-10 US US13/347,302 patent/US8497274B2/en active Active
- 2012-02-14 HK HK12101435.7A patent/HK1161236A1/zh not_active IP Right Cessation
-
2015
- 2015-12-11 HR HRP20151370TT patent/HRP20151370T1/hr unknown
- 2015-12-15 SM SM201500316T patent/SMT201500316B/it unknown
- 2015-12-17 CY CY20151101155T patent/CY1117178T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SMT201500316B (it) | Derivati di benzotiazolo come agenti anticancro | |
SMT201600198B (it) | Derivati di 1,2,4-triazina-4-ammina | |
NL300938I2 (nl) | Niraparib tosylaat of niraparib tosylaat monohydraat | |
SMT201600099B (it) | Derivati citotossici di benzodiazepine | |
SMT201500043B (it) | Indazoli ossazolo-sostituiti come inibitori di pi13-chinasi | |
SMT201400175B (it) | Derivati amminopropionici sostituiti come inibitori di neprilisina | |
SMT201500270B (it) | Derivati di pirrolotriazinone come inibitori di pi3k | |
SMT201500053B (it) | 2-Amminobenzimidazol-5-carbossammidi come agenti nati-infiammatori | |
SMT201600338B (it) | Formulazioni farmaceutiche comprendenti derivati di1-(beta-d- glucopiranosil)- 2-tienilmetilbenzene come inibitori di sglt | |
DK2308877T3 (da) | Imidazopyridin-2-on-derivater | |
DK2634231T3 (da) | Sammensætninger | |
SMT201600076B (it) | Derivati di 2-osso-1-pirrolidinil imidazotiadiazolo | |
BRPI0906980A2 (pt) | Composição de derivados e maleatados | |
ECSP12011999A (es) | Derivados benzamida sustituidos | |
SMAP200900065A (it) | Derivati ciclizzati come inibitori di eg-5 | |
BRPI0913832A2 (pt) | derivados de pirrolopiridinilpirimidin-2-ilamina | |
BRPI0915064A2 (pt) | derivados de qunoxalinadiona | |
SMT201400114B (it) | Derivati di 2-arilimidazolo come inibitori dell'enzima pde10a | |
DK2397480T3 (da) | Diazepindionderivat | |
SMT201400155B (it) | Composizioni farmaceutiche comprendenti derivati di 2-osso-1-pirrolidina | |
SMT201300067B (it) | Applicazioni terapeutiche di derivati di chinazolindione | |
DK2275414T3 (da) | Cyclopentylacrylamidderivat | |
SMT201400080B (it) | Derivati di pirazinoossazepina | |
ATE545635T1 (de) | Substituierte n-oxidpyrazinderivate | |
SMT201500268B (it) | Derivato di 5-idrossipirimidin-4-carbossammide |